arsenic has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chan, R; Feddock, JM; Jyoti, A; Langner, UW; Nagarajan, R; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M | 1 |
Chan, R; Evers, BM; Feddock, JM; Johnson, SE; Jyoti, A; Napier, D; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M; Weiss, HL | 1 |
2 other study(ies) available for arsenic and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Delivery Systems; Endothelial Cells; Female; Fibroblasts; Galectin 1; Mice; Mice, Nude; Nanoparticles; Oxides; Spheroids, Cellular; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Chemoradiotherapy; Cisplatin; Female; Galectin 1; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Oxides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; Young Adult | 2016 |